Jefferies Starts Onyx Pharmaceuticals (ONXX) at Buy
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Jefferies initiates coverage on Onyx Pharmaceuticals (NASDAQ: ONXX) with a Buy. PT $44.00.
The firm comments, "Onyx shares are poised to outperform as the company submits carfilzomib, treatment for multiple myeloma. We estimate 70% likelihood of U.S. approval in 2012 based on our due diligence. Furthermore, Nexavar sales, approved for renal cell cancer and liver cancer, may benefit from near-term clinical data."
For more ratings news on Onyx Pharmaceuticals click here and for the rating history of Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $32.63 yesterday.
The firm comments, "Onyx shares are poised to outperform as the company submits carfilzomib, treatment for multiple myeloma. We estimate 70% likelihood of U.S. approval in 2012 based on our due diligence. Furthermore, Nexavar sales, approved for renal cell cancer and liver cancer, may benefit from near-term clinical data."
For more ratings news on Onyx Pharmaceuticals click here and for the rating history of Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $32.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Aehr Test Systems (AEHR) at Buy
- UBS Starts Schrodinger (SDGR) at Neutral
- BMO Capital Starts Energy Fuels (UUUU) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
